Teriparatide for osteoporosis: importance of the full course

@inproceedings{Lindsay2016TeriparatideFO,
  title={Teriparatide for osteoporosis: importance of the full course},
  author={Robert F. Lindsay and John H. Krege and Fernando Azor{\'i}n Mar{\'i}n and Ling Jin and Jan J. {\vS}těp{\'a}n},
  booktitle={Osteoporosis International},
  year={2016}
}
Teriparatide (TPTD) is the only currently available therapeutic agent that increases the formation of new bone tissue and can provide some remediation of the architectural defects in the osteoporotic skeleton. The use of teriparatide clinically is limited to 24 months. We review clinical findings during daily teriparatide treatment over time. Teriparatide appears to increase bone formation more than bone resorption as determined biochemically and histologically. Teriparatide exerts its positive… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 13 times over the past 90 days. VIEW TWEETS
14 Citations
81 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 81 references

Similar Papers

Loading similar papers…